|
|
|
Pharmaceutical Manufacturing and Packing Sourcer |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. PMPS provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of PMPS |
 |
| |
|
|
|
|
| In her Editor's Letter, Dr Patricia Lobo reviews the articles in this issue of PMPS |
|
|
|
| Emmanuel Dimotakis, PhD and Robert A Nash PhD, Department of Chemical and Pharmaceutical Engineering, New Jersey Institute of Technology, provide a review of matrix and coating systems, in Modified-Release Oral Solid Dosage Forms - Part I: Coating and Matrix Formation |
|
|
| The choice of excipient is extremely critical in formulating direct compression tablets. In Starch Based Excipients for Tabletting, Dr Jacques Michaud, Business Manager Pharma & Cosmetics at Cerestar, considers the suitability of various excipients for direct compression |
|
|
|
| In Improving the Clinical Trial Supply Chain by Using Best Practice Techniques, Harald Geimer and Frank Schulze at PRTM, explore how better manufacturing and supply processes can make the difference between a smooth clinical trial and a costly debacle |
|
|
| Today's CTS business is a microcosm of the wider pharmaceutical industry. In Clinical Trial Supplies - The Essential Link, Dr Patricia Lobo, Editor of PMPS, reviews some aspects of the modern CTS business |
|
|
|
| Bob Clark, Solutions Consultant with the Logos Group of Companies, considers inconsistent use of terminology, quality management and translation, in Taking Control of your Terminology |
|
|
| In The Financial and Operational Benefits of e-Learning in Regulatory Compliance, Chakri Lokapriya, Managing Consultant - Compliance Solutions, and Tony Kypreos, Chief Commercial Officer, at Maersk Data UK, explain why e-learning will improve operational efficiency and profitability |
|
|
| The need to unify automation and information systems has led to the development of a collaborative software architecture. In Putting All The Wood Behind One Arrowhead, Mark Davidson, Vice President of ArchestrA Marketing for Invensys Production Management, examines the results |
|
|
| Tom Lewis, Managing Director of VISiTEMP Limited, answers the question: why do we need temperature data loggers? in Temperature Data Logging - A Primer |
|
|
| In Improving Efficiency and Reducing Costs - What Part Do Information Systems Play? Geoff Parker, Commercial Director at Scimcon, suggests a review of information systems to improve efficiency |
|
|
| Competition in the pharmaceutical industry has intensified and companies must minimise IT downtime to stay ahead of the competition. Russell Flower, Strategy Director at Synstar, explores the components of a global business availability programme, in Are You Available? |
|
|
|
| In The Environmental Impact of Metered Dose Inhalers, Cees Winnips MD, Director of Business Development at SkyePharma AG examines the development of CFC-free alternatives to MDIs |
|
|
| The aim of developing FIDS is to achieve enhanced performance from drugs. Professor John N Staniforth, Chief Scientific Officer at Vectura Ltd, outlines the benefits, in Formulation Integrated Device Systems for Novel Enhanced Performance Products |
|
|
| Sarah Creeke, Andrew Gill, Phil Seeney and Rod Smith, Consultants at PA Consulting group, discuss the performance of dry powder inhalers, in Keep Your Powder Dry |
|
|
| In Nasal Delivery of Vaccines, Dr Per Gisle Djupesland, Founder, Head of R&D and Chairman of OptiNose AS, highlights the advantages of nasal delivery as an attractive alternative to injection |
|
|
|
| Mohan Sasthav PhD, Segment Manager, Packaging, MeadWestvaco Packaging Resources Group, suggests how advanced barrier protection will improve well-being, in The Barrier Essentials |
|
|
| In Packaging - The Future in 3D, Nic Hunt, Global Business Director for Rexam Pharma Flexibles and Rexam Pharma Services, predicts a revolution in virtual packaging design |
|
|
| The closure system used in the packaging of an active substance must be justified for its intended use. Kirsten Nielsen MSc, Head of the Pharmaceutical Packaging Development Department at LEO Pharma A/S, outlines the formula for Packaging for Stability Testing of Active Substances |
|
|
| David Tebworth, Marketing Services Manger at DS Smith Tri-Wall, illustrates aspects of intelligent packaging solutions through all stages of development, focusing on dry flowables, in Intelligent Packaging Solutions for the Distribution of Bulk Chemicals and Pharmaceuticals |
|
|
| In Label Materials For Small Diameter Applications, Sven Tolsma, Product Manager at Raflatac, considers the trend towards smaller diameter packaging and the challenge of labelling these products |
|
|
|
| The validation of disinfectants for use in controlled environments can be both lengthy and expensive. In The Scope of Validation for Cleanroom Disinfectants, Andrew Davidson, Commercial Director of Shield Medicare Ltd, examines how to ensure a smooth and successful outcome |
|
|
| Martyn Ryder, Managing Director of Extract Technology, explores the need for effective dust containment when handling APIs, in Containment Solutions: Solids Charging into Process Vessels |
|
|
| In Acrylic Finishes Wipe the Floor in Hygiene Stakes, Tony Blackman, Technical Manager of Acrylicon, explains the advantages of a new generation of acrylic flooring for cleanrooms |
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
3P Biopharmaceuticals receives FDA approval
[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >> |
|
 |
White Papers |
 |
|
The BioPharmaSpec Approach”: Mass Spectrometry Based Host Cell Protein Identification and Quantitation
BioPharmaSpec
1. Introduction
As part of the development of any biopharmaceutical product, the impurities present must be examined, minimized and where possible characterized (1). These impurities fall into two broad categories: product-related impurities (derived specifically from the drug product itself) and process-related impurities (derived from material associated with the production, processing or purification of the sample). Host cell proteins (HCPs) are process-related impurities that require specific analysis due to the multitude of naturally occurring proteins expressed in the production cell line.
More info >> |
|
 |
Industry Events |
 |
INTERPHEX 2020
15-17 July 2020, Javits Center NYC
More info >> |
|
|
